BR112023019228A2 - Peptídeo e composição contendo o peptídeo - Google Patents

Peptídeo e composição contendo o peptídeo

Info

Publication number
BR112023019228A2
BR112023019228A2 BR112023019228A BR112023019228A BR112023019228A2 BR 112023019228 A2 BR112023019228 A2 BR 112023019228A2 BR 112023019228 A BR112023019228 A BR 112023019228A BR 112023019228 A BR112023019228 A BR 112023019228A BR 112023019228 A2 BR112023019228 A2 BR 112023019228A2
Authority
BR
Brazil
Prior art keywords
peptide
amino acid
composition containing
acid sequence
cha
Prior art date
Application number
BR112023019228A
Other languages
English (en)
Portuguese (pt)
Inventor
Haruaki Kurasaki
Hidetomo Kitamura
Hirofumi Ohashi
Junpei Yamamoto
Katsuma Matsui
Kazutaka Nagatomo
Kei Sudo
Keiichi Masuya
Koichi Watashi
Koji Yoshida
Masaki Ohuchi
Naoko Iwata
Naoko Nakamura
Noriyo Nagata
Nozomi Shiwa
Tadaki Suzuki
Takayuki Nagasawa
Tatsuya Niimi
Yoshiaki Masuda
Yoshiaki Shimada
Original Assignee
Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Peptiaid Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases, Peptiaid Inc filed Critical Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Publication of BR112023019228A2 publication Critical patent/BR112023019228A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023019228A 2021-03-22 2022-03-22 Peptídeo e composição contendo o peptídeo BR112023019228A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021047773 2021-03-22
JP2021192510 2021-11-26
PCT/JP2022/013180 WO2022202816A1 (ja) 2021-03-22 2022-03-22 ペプチド及びペプチドを含む組成物

Publications (1)

Publication Number Publication Date
BR112023019228A2 true BR112023019228A2 (pt) 2023-11-28

Family

ID=83395638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019228A BR112023019228A2 (pt) 2021-03-22 2022-03-22 Peptídeo e composição contendo o peptídeo

Country Status (11)

Country Link
US (1) US20240209027A1 (https=)
EP (1) EP4317174A4 (https=)
JP (1) JPWO2022202816A1 (https=)
KR (1) KR20230170918A (https=)
AU (1) AU2022242421A1 (https=)
BR (1) BR112023019228A2 (https=)
CA (1) CA3214455A1 (https=)
IL (1) IL307225A (https=)
MX (1) MX2023011194A (https=)
TW (1) TW202304947A (https=)
WO (1) WO2022202816A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
US20250250299A1 (en) * 2022-03-28 2025-08-07 Bristol-Myers Squibb Company Macrocyclic immunomodulators
CN116445523B (zh) * 2023-04-10 2024-05-07 西北农林科技大学 一种小麦抗逆性基因TaBSL3与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US8658604B2 (en) * 2005-02-17 2014-02-25 Polyphor Ltd Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
WO2007066627A1 (ja) 2005-12-06 2007-06-14 The University Of Tokyo 多目的アシル化触媒とその用途
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US20160068835A1 (en) 2013-01-30 2016-03-10 Peptidream Inc. Flexible display method
CN111349150B (zh) * 2020-03-24 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制新型冠状病毒的多肽及其用途
CN111471088B (zh) * 2020-04-21 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制sars-cov-2感染的多肽、组合物及其用途
CN111643656B (zh) * 2020-05-14 2022-07-19 悦康药业集团股份有限公司 广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用
CN111732637B (zh) * 2020-05-25 2022-03-01 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用
CN112630444B (zh) * 2020-12-11 2024-05-24 深圳碳云智肽药物科技有限公司 基于靶点蛋白的多肽筛选方法

Also Published As

Publication number Publication date
EP4317174A4 (en) 2025-04-02
KR20230170918A (ko) 2023-12-19
WO2022202816A1 (ja) 2022-09-29
TW202304947A (zh) 2023-02-01
US20240209027A1 (en) 2024-06-27
EP4317174A1 (en) 2024-02-07
CA3214455A1 (en) 2022-09-29
AU2022242421A2 (en) 2023-11-16
AU2022242421A1 (en) 2023-11-02
MX2023011194A (es) 2024-01-04
IL307225A (en) 2023-11-01
JPWO2022202816A1 (https=) 2022-09-29

Similar Documents

Publication Publication Date Title
BR112023019228A2 (pt) Peptídeo e composição contendo o peptídeo
BR112021017603A2 (pt) Vírus adenoassociado (aav) mutante tendo propriedade de direcionamento para o cérebro
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
Hille et al. Tyrosine sulfation: a post‐translational modification of proteins destined for secretion?
Baxter et al. Radiocarbon dating of mortars
BR112021021912A2 (pt) Nova nuclease omni-50 crispr
ATE140969T1 (de) Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BR112023022398A2 (pt) Composições e método para vacinas peptídicas otimizadas usando otimização de resíduos
MX9202724A (es) Composicion que comprende un vector recombinante del agente lelystad y vacuna que comprende la misma.
BR0207854A (pt) Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
BR112013013548B8 (pt) Proteína de fusão anticancerígena
BR112022003760A2 (pt) Análogos de compstatina e seus usos médicos
ATE387205T1 (de) Zusammensetzungen zur behandlung von durch c. difficile toxin b verursachten durchfallerkrankungen (cdad)
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
BR112022015232A2 (pt) Peptídeo cíclico, composição farmacêutica e solução aquosa de um peptídeo específico de receptor de melanocortina com um valor ec50 menor que 1 nm em cada dentre mc1r e mc5r
BRPI0507186A (pt) composição, métodos e usos para uma nova famìlia de peptìdeos
BR112022024667A2 (pt) Composições e métodos para aumentar enxertos de gordura autólogos
Hase et al. Amino acid sequence of Chromatium vinosum ferredoxin: revisions
BR112023021094A2 (pt) Composição condicionadora de tecido, método de preparação de uma composição condicionadora de tecido e uso de carbono derivado da captura de carbono
BR0107827A (pt) Atenuação recombinante de prrsv

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]